Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2126-2133

  Niwa, Takashi ^a   Suzuki, Akio ^a   Sakakibara, Seiji ^a   Kasahara, Senji ^a   Yasuda, Mitsuru ^a   Fukao, Ayumi ^a   Matsuura, Katsuhiko ^a   Goto, Chitoshi ^a   Murakami, Nobuo ^a   Itoh, Yoshinori ^a,b  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

dose per body weight; linezolid; renal insufficiency; risk factor; thrombocytopenia

Indexed keywords

CREATININE; LINEZOLID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GRAM POSITIVE INFECTION; HEMODIALYSIS; HUMAN; JAPAN; JAPANESE; KIDNEY FAILURE; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CREATINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; OXAZOLIDINONES; PLATELET COUNT; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 71549145612     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.017     Document Type: Article

References (32)

1. Fung H.B., Kirschenbaum H.L., and Ojofeitimi B.O. Linezolid: An oxazolidinone antimicrobial agent. Clin Ther 23 (2001) 356-391
2. Steinmetz M.P., Vogelbaum M.A., De Georgia M.A., et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: Case report and review of the literature. Crit Care Med. 29 (2001) 2383-2385
3. Wilson S.E. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative grampositive infections. Surg Infect (Larchmt) 2 (2001) 25-35
4. Sztanke K., Pasternak K., and Sztanke M. Oxazolidinonesa new class of broad-spectrum chemotherapeutics. Ann Univ Mariae Curie Sklodowska Med. 59 (2004) 335-341
5. Renslo A.R., Jaishankar P., Venkatachalam R., et al. Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0] hexylphenyl)oxazolidinones. J Med Chem 48 (2005) 5009-5024
6. Kaya O., Akcam F.Z., and Temel E.N. In vitro activities of linezolid and tigecycline against methicillin-resistant Staphylococcus aureus strains. Microb Drug Resist 14 (2008) 151-153
7. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 8 (1999) 1195-1202
8. Thompson J., O'Connor M., Mills J.A., and Dahlberg A.E. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol 322 (2002) 273-279
9. Champney W.S., and Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 44 (2002) 350-356
10. Zhanel G.G., Shroeder C., Vercaigne L., et al. A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins?. Can J Infect Dis. 12 (2001) 379-390
11. MacGowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51 Suppl 2 (2003) 1117-1125
12. Waldrep T.W., and Skiest D.J. Linezolidinduced anemia and thrombocytopenia. Pharmacotherapy 22 (2002) 109-112
13. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
14. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 51 Suppl 2 (2003) ii45-ii53
15. Senneville E., Legout L., Valette M., et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: A case-control study. J Antimicrob Chemother 54 (2004) 798-802
16. Wu V.C., Wang Y.T., Wang C.Y., et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 42 (2006) 66-72
17. Bishop E., Melvani S., Howden B.P., et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: A proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50 (2006) 1599-1602
18. Lin Y.H., Wu V.C., Tsai I.J., et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 28 (2006) 345-351
19. Rao N., and Hamilton C.W. Efficacy and safety of linezolid for Gram-positive orthopedic infections: A prospective case series. Diagn Microbiol Infect Dis. 59 (2007) 173-179
20. Attassi K., Hershberger E., Alam R., and Zervos M.J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 34 (2002) 695-698
21. Soriano A., Ortega M., García S., et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Anti-microb Agents Chemother 51 (2007) 2559-2563
22. Pfizer. Zyvox (linezolid) [package insert]. http:www.info.pmda.go.jp/downfiles/ph/PF/40079_6249401A1025_3_11.pdf Accessed June 22, 2009
23. US Food and Drug Administration. Zyvox (linezolid) [prescribing information]. US FDA Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails Accessed June 20, 2009
24. Fujiwara Y., and Kobayashi K. Oncology drug clinical development and approval in Japan: The role of the pharmaceuticals and medical devices evaluation center (PMDEC). Crit Rev Oncol Hemat 42 (2002) 145-155
25. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
26. Grau S., Morales-Molina J.A., Mateu-de Antonio J., et al. Linezolid: Low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 56 (2005) 440-441
27. Whitehouse T., Cepeda J.A., Shulman R., et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 55 (2005) 333-340
28. Slatter J.G., Stalker D.J., Feenstra K.L., et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 29 (2001) 1136-1145
29. Brier M.E., Stalker D.J., Aronoff G.R., et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 47 (2003) 2775-2780
30. Tsuji Y., Hiraki Y., Mizoguchi A., et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 14 (2008) 156-160
31. Rao N., Ziran B.H., Wagener M.M., et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 38 (2004) 1058-1064
32. Nasraway S.A., Shorr A.F., Kuter D.J., et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: Comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 37 (2003) 1609-1616